Preventing SCD With a WCD: Reviewing the Results of the VEST Trial

Slides:

Advertisements

Similar presentations

Hypertrophic Cardiomyopathy Guidelines Summary from the: ACC/ESC Clinical Expert Consensus Statement on Hypertrophic Cardiomyopathy Maron BJ, et al. J.

Advertisements

Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)

Atrial Fibrillation and Sudden Death: Are they linked? Mariell Jessup MD Professor of Medicine University of Pennsylvania Philadelphia, Pennsylvania.

Primary Prevention ICD Therapy: Tools to Enhance Guideline Compliance By: Margaret S. Thomas, RN,CVRN Michael J. Mirro, MD Alicia S. Floor, AS,RN, Rob.

ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.

Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.

Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,

IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.

IMPLANTABLE DEFIBRILLATOR By: Victor J. Gabbidon.

EP Show – Dec 2003 ICDs – Primary prevention The EP Show: Guidelines and reimbursement at the crossroads: Primary prevention with ICDs Eric Prystowsky.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:

Ventricular Arrhythmias:A General Cardiologist’s Assessment of Therapies in 2004 C.Richard Conti M.D. MACC.

Defibrillator in Acute Myocardial Infarction Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Drs. Stewart Connelly.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Wearable Cardioverter-Defibrillator Use in Patients.

Wearable Cardioverter Defibrillators

Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in CKD: A Meta-analysis of Patient-Level Data From 3 Randomized.

Presented By James Hill at 2016 ASCO Annual Meeting

Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness.

Defibrillator in Acute Myocardial Infarction Trial

Addressing the Challenges in Primary and Secondary Stroke Prevention

Brugada’s Syndrome and Sudden Cardiac Death

The Anglo Scandinavian Cardiac Outcomes Trial

PCSK9 Inhibitors Post-CVOTs

New Guidelines to Prevent SCD: What You Need to Know

CathPCI-NCDR Registry Mortality (STEMI)

Acute Heart Failure.

Addressing Patients at High Risk for SCA

DANISH Trial design: Patients with nonischemic cardiomyopathy were randomized to ICD implantation (n = 556) versus usual care (n = 560). Results (p = 0.28)

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

It’s Elementary.

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection Derek V. Exner, MD, MPH, David.

Antithrombotics and PAD: A New Paradigm in Practice

Treating HFrEF: Challenges Faced

Are We Closer to Personalized Medicine in MS?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

Efficacy and Safety of Edoxaban in Patients With AF and HF

MASTER Trial Inclusion Criteria

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Risk Stratification in CAD and PAD

Remote Patient Management:

Misconceptions and Facts About Hypertrophic Cardiomyopathy

Overcoming Clinical Inertia

Aspirin and Cardioprevention in 2018

Belinda Gray et al. JCHF 2013;1:

The EP Show: CMS reimbursement decision for ICDs

ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then.

David F. Katz et al. JACEP 2016;j.jacep

Factor Xa Inhibitors in PAD

Mahesh Anantha Narayanan et al. JACEP 2017;3:

The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.

Program Goals Background: Anticoagulation in Patients With VTE.

Elevated Admission Plasma Glucose Following ACS

Outcomes After Ventricular Fibrillation Out-of-Hospital Cardiac Arrest: Expanding the Chain of Survival T. Jared Bunch, MD, Stephen C. Hammill, MD, Roger.

Practical Tools for SCA Screening

David F. Katz et al. JACEP 2017;3:20-28

Volume 12, Issue 10, Pages (October 2015)

2015 EASD In Review: CV Risk management in t2dm

Mahesh Anantha Narayanan et al. JACEP 2017;j.jacep

The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter

Jordan S. Leyton-Mange et al. JACEP 2017;j.jacep

Omega-3s vs Pure EPA in Clinical Practice

Evaluating the Science of Cardiogenic Shock

Figure 1 Distribution of WCD use days in WEARIT-II

My PAH Patient.

Rethinking Risk Stratification for Nonischemic HF:

The Power of As-Treated Analyses

What's New in NOACs in AF?.

Presentation transcript:

Preventing SCD With a WCD: Reviewing the Results of the VEST Trial

Overview

2017 ACC/AHA/HRS Guideline on the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

Risk Stratification

Early ICD Not Advisable

Wearable Cardioverter-Defibrillator

Primary Prevention of SCD in Patients With IHD

Waiting Period for ICD

Secondary and Primary Prevention of SCD in Patients With Nonischemic Cardiomyopathy

Current Indications for WCD

Wearable Cardioverter Defibrillator

Observational Studies of WCD Patient Types Studied

Aggregate US Nationwide Data on WCD

Aggregate Germany Nationwide Data on WCD

Rationale for VEST Trial

VEST Eligibility Criteria

VEST Design

VEST Design (cont)

VEST Screening and Enrollment

VEST Results: Demographics

VEST Results: Characteristics of Index MI

VEST Results: Medical Treatment

VEST Results: Crossover Treatment

VEST Results: WCD Wear Time

VEST Results: Primary Outcome

VEST Results: Non-Sudden Death

VEST Results: Death From Any Cause

VEST: Sudden Death vs Total Mortality

Applying VEST Results to Clinical Care

Applying VEST Results to Clinical Care (cont)

Shared Decision-Making

Abbreviations

Abbreviations (cont)